Clinical Trial Detail

NCT ID NCT02181738
Title Study of Nivolumab in Subjects With Hodgkin's Lymphoma (Registrational) (CheckMate 205)
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements no
Sponsors Bristol-Myers Squibb
Indications

Hodgkin's lymphoma

Therapies

Nivolumab

Age Groups: adult

No variant requirements are available.